OCX 2.73 Stock Price OncoCyte Corporation
Range: | 2.285-4.305 | Vol Avg: | 33434 | Last Div: | 0 | Changes: | 0.02 |
Beta: | 1 | Cap: | 0.05B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Wed Dec 30 2015 | Empoloyees: | 43 |
CUSIP: | 68235C107 | CIK: | 0001642380 | ISIN: | US68235C2061 | Country: | US |
CEO: | Mr. Joshua Riggs | Website: | https://oncocyte.com |
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.